Posted by Michael Wonder on 26 Oct 2023
FDA approves Lilly's Omvoh (mirikizumab-mrkz), a first in class treatment for adults with moderately to severely active ulcerative colitis
26 October 2023 - Omvoh achieved primary and key secondary endpoints, including sustained clinical remission in pivotal trials.
Eli Lilly announced today that the US FDA has approved Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 antagonist for the treatment of moderately to severely active ulcerative colitis in adults.
